Anti-tumor necrosis factor-alpha-induced psoriasis.

SARI İ., Akar S., Birlik M., Sis B., Onen F., Akkoc N.

The Journal of rheumatology, cilt.33, sa.7, ss.1411-4, 2006 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 33 Sayı: 7
  • Basım Tarihi: 2006
  • Dergi Adı: The Journal of rheumatology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1411-4
  • Anahtar Kelimeler: tumor necrosis factor-alpha inhibitors, psoriasis, adverse effect, ANKYLOSING-SPONDYLITIS, RHEUMATOID-ARTHRITIS, NEW-ONSET, EXACERBATION, THERAPY, CLASSIFICATION, INFLIXIMAB, CRITERIA, LESIONS, AGENTS
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

We describe a patient with rheumatoid arthritis who developed psoriasis during treatment with etanercept; psoriatic lesions resolved completely after the drug was discontinued. but returned on rechallenge. No such adverse skin reaction occurred after switching therapy to infliximab. Through a Medline search we identified 11 reports involving 32 patients who developed psoriasis/psoriasiform eruptions during therapy with tumor necrosis factor-alpha (TNF-alpha) inhibitors. All TNF-alpha blocking agents have been reported to lead to or exacerbate psoriasis. In some cases skin changes were severe enough to discontinue the medication.